EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Oncolytic virus-induced IL-1β + monocyte-IL-6 + CAF axis suppresses dendritic cell-mediated antitumor immunity in pancreatic cancer

Fan Li, Jingru Chen, Yuanke Li, Wei Wang, Yi Yang, Jie Wang, Minghui Han, Han Wang, Feilong Zhou, Wenxuan Ma, Yi Wang, Zhaoyuan Zhang und 10 weitere

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2025-013175 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Fan Li und 21 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Frontiers Science Centre for Cell Responses, CNBG-Nankai University Joi…. Hauptthemen laut MEDLINE: Dendritic Cells, Pancreatic Neoplasms, Monocytes, Cancer-Associated Fibroblasts. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, CNBG-Nankai University joint Research and Development Center Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a profoundly immunosuppressive tumor microenvironment, which features a dense desmoplastic stroma enriched with cancer-associated fibroblasts (CAFs) that collectively impede the efficacy of immunotherapies. Although oncolytic viruses (OVs) have demonstrated promising potential in eliciting antitumor immunity, the mechanisms by which stromal components modulate OV efficacy remain poorly understood.

Methods

To investigate the interplay between immune and stromal components in PDAC following OV treatment, we employed murine and patient-derived tumor models. We characterized immune cell populations using single-cell RNA sequencing and flow cytometry. Functional studies included the engineering of a next-generation oncolytic herpes simplex virus expressing FLT3 ligand, OX40 ligand, and interleukin-12 (IL-12), combined with CD40 agonist antibodies to restore dendritic cell (DC) function and enhance T-cell responses.

Results

We identified a novel immunosuppressive circuit wherein monocytes, sensing damage-associated molecular patterns and pathogen-associated molecular patterns from OV-infected tumor cells, secrete interleukin-1β. This, in turn, triggers IL-6 production by CAFs, creating an IL-6-rich milieu that impairs DC maturation and co-stimulatory signaling, thereby attenuating T cell-mediated antitumor immunity and restricting OV therapeutic efficacy. Importantly, combination therapy with the engineered OV and CD40 agonist antibodies restored DC functionality and elicited robust tumor-specific T-cell responses in both murine and patient-derived models.

Conclusion

Our findings reveal a previously unrecognized monocyte-CAF-DC axis that mediates resistance to OV therapy through IL-1β and IL-6-driven suppression of DC function in PDAC. This study provides a mechanistically informed and translationally promising approach to overcome stromal immune suppression, restore effective antitumor immunity, and improve therapeutic outcomes for patients with PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsPancreatic NeoplasmsMonocytesCancer-Associated FibroblastsOncolytic VirusesInterleukin-1betaInterleukin-6Carcinoma, Pancreatic DuctalOncolytic VirotherapyAnimalsMiceHumansTumor MicroenvironmentCell Line, TumorFemale

Stichwörter der Autor:innen

Combination therapyDendriticImmunosuppressionImmunotherapyOncolytic virus

Substanzen

Interleukin-1betaInterleukin-6

Autor:innen und Institutionen

  • State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Frontiers Science Centre for Cell Responses, CNBG-Nankai University Joint Research and Development Center, Academy for Advanced Interdiscipli…
  • School of Health Science & Biomedical Engineering, Hebei University of Technology, Tianjin, China.
  • Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
  • The Chinese University of Hong Kong Faculty of Medicine, Hong Kong, China.
  • Clinical Center for Biotherapy&Zhongshan Hospital, Fudan University, Shanghai, China.
  • Beijing Institute of Biological Products Company Limited and CNBG-Nankai University Joint Research and Development Center, Beijing, China.

Förderung

  • National Natural Science Foundation of China
  • CNBG-Nankai University joint Research and Development Center Funding

Zitieren

APA

Li, F., Chen, J., Li, Y., Wang, W., Yang, Y., Wang, J., Han, M., Wang, H., Zhou, F., Ma, W., Wang, Y., Zhang, Z., Yu, J., Zhao, Z., Deng, L., Liu, S., Wan, Y., Zhao, Z., Xu, S., …, & Zhang, H. (2025). Oncolytic virus-induced IL-1β + monocyte-IL-6 + CAF axis suppresses dendritic cell-mediated antitumor immunity in pancreatic cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-013175

Vancouver

Li F, Chen J, Li Y, Wang W, Yang Y, Wang J, et al. Oncolytic virus-induced IL-1β + monocyte-IL-6 + CAF axis suppresses dendritic cell-mediated antitumor immunity in pancreatic cancer. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2025-013175

BibTeX
@article{Li2025,
  author = {Li, Fan and Chen, Jingru and Li, Yuanke and Wang, Wei and Yang, Yi and Wang, Jie and Han, Minghui and Wang, Han and Zhou, Feilong and Ma, Wenxuan and Wang, Yi and Zhang, Zhaoyuan and Yu, Junfeng and Zhao, Zhen and Deng, Li and Liu, Shiyu and Wan, Yajuan and Zhao, Zhigang and Xu, Song and Li, Jiangmei and Cao, Youjia and Zhang, Hongkai},
  title = {Oncolytic virus-induced IL-1β + monocyte-IL-6 + CAF axis suppresses dendritic cell-mediated antitumor immunity in pancreatic cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2025-013175}
}
Kostenlos starten →